Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 249

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Open access
Pollyea, Daniel A., Tallman, Martin S., de Botton, Stéphane, Kantarjian, Hagop M., Collins, Robert, Stein, Anthony S., Frattini, Mark G., Xu, Qiang, Tosolini, Alessandra, See, Wendy L., MacBeth, Kyle J., Agresta, Samuel V., Attar, Eyal C., DiNardo, Courtney D., Stein, Eytan M. · 2019 · Leukemia

Abstract

Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12-15% of older patients with AML harbor isocitrate dehydrogenase 2 (IDH2) gene mutations. Enasidenib is an oral inhibitor of mutant IDH2 proteins. Among 39 patients with newly diagnosed mutant-IDH2 AML who received enasidenib monotherapy in this phase I/II trial, median age was 77 years (range 58-87) and 23 patients (59%) had had an antecedent hematologic disorder. The median number of enasidenib treatment cycles was 6.0 (range 1-35). The most common treatment-related adverse events were indirect hyperbilirubinemia (31%), nausea (23%), and fatigue, decreased appetite, and rash (18% each). Treatment-related grade 3-4 cytopenias were reported for eight patients (21%); there was no treatment-related grade 3-4 infections. Twelve patients achieved a response (overall response rate 30.8% [95% CI 17.0%, 47.6%]), including seven patients (18%) who attained complete remission. At a median follow-up of 8.4 months, the median duration of any response was not reached (NR). Median overall survival for all patients was 11.3 months (95% CI 5.7, 15.1), and was NR for responders. Oral, outpatient targeted treatment with enasidenib may benefit older adults with newly diagnosed mutant-IDH2 AML who are not candidates for cytotoxic regimens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-019-0472-2

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 249

Metadata

Authors
Pollyea, D. A., Tallman, M. S., de Botton, S., Kantarjian, H. M., Collins, R., Stein, A. S., Frattini, M. G., Xu, Q., Tosolini, A., See, W. L., MacBeth, K. J., Agresta, S. V., Attar, E. C., DiNardo, C. D., & Stein, E. M.
Venue
Leukemia
Published
2019-04-09
Volume
33
Issue
11
Pages
2575-2584
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2939577741
Cited by
249
References
8
FWCI
23.42
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. https://app.cochat.ai/papers/10.1038/s41375-019-0472-2
The paper
Pollyea, D. A., Tallman, M. S., de Botton, S., Kantarjian, H. M., Collins, R., Stein, A. S., Frattini, M. G., Xu, Q., Tosolini, A., See, W. L., MacBeth, K. J., Agresta, S. V., Attar, E. C., DiNardo, C. D., & Stein, E. M. (2019). Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. https://doi.org/10.1038/s41375-019-0472-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.